A revised price target for Rithm Capital (NYSE: RITM) has prompted a fresh look at the mortgage REIT's prospects, with analysts weighing its strategic shifts against a complex macroeconomic backdrop.
The Central American nation makes its second major gold purchase in months, fortifying reserves as it balances pioneering Bitcoin bets with traditional safe-haven assets during a period of market volatility.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Exco Technologies Ltd. (TSE:XTC) kicked off its fiscal 2026 with a solid first quarter, posting higher profits despite a mixed demand environment. Robust growth in its Automotive Solutions segment successfully countered softer demand in its die-cast tooling business, showcasing the resilience of its diversified model amid ongoing trade policy and economic uncertainty.
Champion Iron reports steady Q3 operational performance with improved costs and significant progress on its high-grade DRPF project. The company also details the fully-financed plan to acquire Norway's Rana Gruber, aiming to strengthen its foothold in the European steelmaking market.
Facing headwinds from tariffs, a soft housing market, and intense promotions, Whirlpool reported flat organic revenue for 2025. Executives outlined a plan to improve margins and cash flow in the coming year, banking on pricing normalization and new product launches.
British Prime Minister Keir Starmer arrived in Shanghai Friday with over 50 business leaders, aiming to deepen UK-China commercial ties. The visit, the first by a UK premier in eight years, comes against a backdrop of renewed US skepticism over Western engagement with Beijing.
Bitcoin tumbled toward $81,000 as markets reacted to the potential nomination of former Fed Governor Kevin Warsh, whose history of monetary hawkishness is viewed as a headwind for risk assets like cryptocurrency.
Bitcoin's volatility gauge spiked sharply during Thursday's sell-off, signaling heightened trader anxiety and a rush for downside protection, though metrics suggest the market is not yet in extreme fear territory.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
President Trump is expected to nominate former Fed governor Kevin Warsh as Jerome Powell's successor, a move markets interpret as a tilt toward more hawkish monetary policy and an end to months of uncertainty over the central bank's leadership.
The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
The French government has intervened to stop satellite operator Eutelsat from selling its ground antenna assets, framing the move as a defense of European strategic autonomy against rivals like SpaceX's Starlink.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
